Indian Journal of Dermatology, Venereology and Leprology
Medknow Publications on behalf of The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)
Vol. 70, No. 5, 2004, pp. 288-291
Bioline Code: dv04099
Full paper language: English
Document type: Research Article
Document available free of charge
Indian Journal of Dermatology, Venereology and Leprology, Vol. 70, No. 5, 2004, pp. 288-291
© Copyright 2004 Indian Journal of Dermatology, Venereology, Leprology.
Study - Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: A post-marketing surveillance study|
Bhankharia DimpleA, Sanjana PercyH
Desonide, a non-halogenated, low-potency topical steroid, is indicated in the treatment of steroid-responsive dermatoses.
A post-marketing surveillance study was conducted to evaluate the efficacy and safety of DesowenTM (Desonide 0.05%) cream and lotion in Indian patients for the treatment of steroid-responsive dermatoses of mild to moderate severity.
A 3-week, multicenter, open-label, non-comparative Phase IV trial involving 1789 patients from 229 centers across India was conducted between January and August 2003.
Of the 1789 patients, 1483 patients completed the treatment as per protocol. At the end of the therapy, 98.5% of the patients showed an improvement in their dermatitis from baseline. More than half of the patients showed a greater than 75% improvement in their signs and symptoms. No adverse effects were noted in any of the patients. Both the lotion and cream were found to be equally effective.
Desonide 0.05% is a safe and effective low-potency corticosteroid for the treatment of mild to moderate dermatoses in Indian patients. No clinically apparent side-effects were observed in infants less than 1 year of age.
Desonide, Steroid-responsive dermatoses, Safety, Efficacy, Indian patients, Infants
Alternative site location: http://www.ijdvl.com